StocksMedium•10 November 2026•
1 min read
MaxCyte Reports $10.2M Q3 Revenue and Raises Full-Year 2026 Guidance
Key Facts
1MaxCyte reported total revenue of $10.2 million for the third quarter of 2026.
2The company raised its full-year 2026 total revenue guidance to at least $34.5 million.
3MaxCyte announced the proposed acquisition of Akron Bio to expand its cell therapy manufacturing offerings.
MaxCyte reported total revenue of $10.2 million for the third quarter of 2026, according to GlobeNewswire. Following these results, the company raised its full-year 2026 total revenue guidance to at least $34.5 million. Additionally, MaxCyte announced the proposed acquisition of Akron Bio to expand its specialized offerings in cell therapy manufacturing.
MXCT closed at $1.3 on November 9, 2026, prior to the release of the financial results and the updated guidance. The acquisition of Akron Bio, a supplier of GMP-grade reagents, aligns with the company's strategic expansion of its platform and customer base as it demonstrates a return to revenue growth.